AU2019224550A1 - Ligands to GM-CSF or GM-CSF-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-HCT - Google Patents

Ligands to GM-CSF or GM-CSF-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-HCT Download PDF

Info

Publication number
AU2019224550A1
AU2019224550A1 AU2019224550A AU2019224550A AU2019224550A1 AU 2019224550 A1 AU2019224550 A1 AU 2019224550A1 AU 2019224550 A AU2019224550 A AU 2019224550A AU 2019224550 A AU2019224550 A AU 2019224550A AU 2019224550 A1 AU2019224550 A1 AU 2019224550A1
Authority
AU
Australia
Prior art keywords
csf
hct
ligand
patient
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019224550A
Other languages
English (en)
Inventor
Burkhard Becher
Sonia TUGUES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18194549.4A external-priority patent/EP3623382A1/en
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of AU2019224550A1 publication Critical patent/AU2019224550A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019224550A 2018-02-22 2019-02-22 Ligands to GM-CSF or GM-CSF-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-HCT Abandoned AU2019224550A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP18158169 2018-02-22
EP18158169.5 2018-02-22
EP18189562 2018-08-17
EP18189562.4 2018-08-17
EP18194549.4 2018-09-14
EP18194549.4A EP3623382A1 (en) 2018-09-14 2018-09-14 Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US16/269,572 US11655293B2 (en) 2018-02-22 2019-02-07 Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
US16/269,572 2019-02-07
PCT/EP2019/054493 WO2019162472A1 (en) 2018-02-22 2019-02-22 Ligands to gm-csf or gm-csf-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-hct

Publications (1)

Publication Number Publication Date
AU2019224550A1 true AU2019224550A1 (en) 2020-09-17

Family

ID=67616687

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019224550A Abandoned AU2019224550A1 (en) 2018-02-22 2019-02-22 Ligands to GM-CSF or GM-CSF-receptor for use in treatment of a haematologic malignancy in a patient having undergone allo-HCT

Country Status (11)

Country Link
US (3) US11655293B2 (enExample)
EP (1) EP3755715A1 (enExample)
JP (1) JP7278296B2 (enExample)
KR (1) KR20200123434A (enExample)
CN (1) CN111886248B (enExample)
AU (1) AU2019224550A1 (enExample)
BR (1) BR112020017253A2 (enExample)
CA (1) CA3091536A1 (enExample)
MA (1) MA51893A (enExample)
MX (2) MX2020008792A (enExample)
WO (1) WO2019162472A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
CA3229748A1 (en) * 2021-08-26 2023-03-02 Akifumi Kato Bispecific antibody that binds to cd116 and cd131

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367688A (zh) 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
CN104072613A (zh) 2007-11-13 2014-10-01 Evec股份有限公司 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CA2717987C (en) 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
MA37946B1 (fr) 2012-09-20 2018-09-28 Morphosys Ag Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
US9658228B2 (en) * 2013-01-30 2017-05-23 The Board of Trustees of the Leland University Junior University Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
JP6490419B2 (ja) 2014-12-24 2019-03-27 学校法人関西医科大学 制御性ｔ細胞分化誘導剤
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT

Also Published As

Publication number Publication date
JP7278296B2 (ja) 2023-05-19
BR112020017253A2 (pt) 2020-12-22
MX2020008792A (es) 2020-10-14
RU2020129401A (ru) 2022-03-22
JP2021514368A (ja) 2021-06-10
US20210070851A1 (en) 2021-03-11
US11655293B2 (en) 2023-05-23
RU2020129401A3 (enExample) 2022-03-22
US20190256587A1 (en) 2019-08-22
MA51893A (fr) 2020-12-30
KR20200123434A (ko) 2020-10-29
CN111886248B (zh) 2025-03-04
EP3755715A1 (en) 2020-12-30
CA3091536A1 (en) 2019-08-29
WO2019162472A1 (en) 2019-08-29
US20230340100A1 (en) 2023-10-26
MX2023001357A (es) 2023-02-27
US12384839B2 (en) 2025-08-12
CN111886248A (zh) 2020-11-03

Similar Documents

Publication Publication Date Title
US12384839B2 (en) Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
Lavender et al. BLT-humanized C57BL/6 Rag2−/− γ c−/− CD47−/− mice are resistant to GVHD and develop B-and T-cell immunity to HIV infection
Zhou et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Shin et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+ CD25+ Foxp3+ regulatory T cells
US20250197498A1 (en) Methods for in vivo expansion of cd8+ t cells and prevention or treatment of gvhd
Johnston et al. Administration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effects
WO2022241475A1 (en) Targeting extracellular matrix proteins to regulate nk cell function in peripheral tissues
US20230210984A1 (en) Adoptive immunotherapy
US20240226168A1 (en) Engineered nk cells and uses thereof
EP3623382A1 (en) Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
RU2772132C2 (ru) Лиганды гм-ксф или рецептора гм-ксф для применения при лечении гемобластоза у пациента, перенесшего алло-тгк
JP5626990B2 (ja) Ｔｈ２細胞誘導用組成物およびＴｈ２型疾患の治療組成物、ならびにこれらの利用
Field Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Powell Fetoplacental-derived extracellular vesicles: a mechanism of feto-maternal communication in pregnancy
Buckle Antigen-specific peptide immunotherapy for treatment and prevention of type 1 diabetes
Gaignage et al. TLR7ligandR848preventsmousegraft-versus-hostdiseaseandcooperates withanti-IL-27antibodyformaximalprotectionandTregupregulation
WO2020247432A1 (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
Alizadeh Doxorubicin and T helper lymphocytes: Unexpected allies against cancer
De Vries Regulation of peripheral tolerance by mast cells
Vernon HMGB1, RAGE, and the Myeloid Response to Pancreatic Cancer
Parker et al. Vitamin D Inhibits the Occurrence of
Wu et al. Ed summary: Chimeric antigen receptor macrophages including the MyD88 activation domain target mesothelin for treatment of lung cancer brain metastases
Cao et al. REGULATORY IMMUNE CELLS IN KIDNEY DISEASE
Cabrera-Pérez Examining helper T-cell recovery after sepsis
WO2016074580A1 (zh) 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted